MGBBP-3 is under clinical development by MGB Biopharma and currently in Phase II for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase II drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MGBBP-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MGBBP-3 is under development for the treatment of Clostridium difficile infections, gram-positive bacteria which includes methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), Streptococcal infections, Staphylococcus aureus (HA-MRSA) infections. The drug candidate is administered through oral route as a capsule and tablet, intravenous route as a solution and topical route as a cream. It is an anti-bacterial minor groove binder (AbMGB) agent that acts by targeting DNA. The drug candidate is developed based on DNA minor groove binder (MGB) technology. It was also under development for Enterococcus infections, Neisseria meningitides and Moraxella catarrhalis.
MGB Biopharma overview
MGB Biopharma is a biopharmaceutical company that develops a novel class of anti-infectives using Minor Groove Binder (MGB) compounds. Its lead drug candidate MGB-BP-3 in the field of antibacterial resistance is active against many Gram-positive bacteria. MGB Biopharma also developed an oral formulation of MGB-BP-3 for Clostridium difficile. The company’s technology platform provides an opportunity to develop various compounds against multi-resistant Gram-negative pathogens, fungi, viruses, and parasitic diseases. It works in partnership with the University of Strathclyde, and other pharmaceutical companies for the advancement of its novel anti-infective platform. MGB Biopharma is headquartered in Bellshill, Scotland, the UK.
For a complete picture of MGBBP-3’s drug-specific PTSR and LoA scores, buy the report here.